RNA sequencing (RNA-seq) technologies have been popularly applied to study gene expression in recent years. Identifying differentially expressed (DE) genes across treatments is one of the major steps in RNA-seq data analysis. Most differential expression analysis methods rely on parametric assumptions, and it is not guaranteed that these assumptions are appropriate for real data analysis. In this paper, we develop a semi-parametric Bayesian approach for differential expression analysis. More specifically, we model the RNA-seq count data with a Poisson-Gamma mixture model, and propose a Bayesian mixture modeling procedure with a Dirichlet process as the prior model for the distribution of fold changes between the two treatment means. We develop Markov chain Monte Carlo (MCMC) posterior simulation using Metropolis Hastings algorithm to generate posterior samples for differential expression analysis while controlling false discovery rate. Simulation results demonstrate that our proposed method outperforms other popular methods used for detecting DE genes. 14 Otherwise, the gene is said to be equivalently expressed (EE). Generally, negative 15 binomial (NB) distribution is used for modeling RNA-seq count data. Many statistical 16 methods based on the NB distribution have been proposed for detecting DE genes with 17 RNA-seq data, including edgeR [1-4], DESeq [5] and DESeq2 [6]. Methods that do not 18 assume NB models typically involves transformation of the count data to continuous 19 scale, such as the Voom and limma pipeline [7], which models the mean-variance 20 relationship of the log-transformed count data and produces a precision weight for each 21 October 2, 2018 1/13 observation, then applies the limma method based on normal distributions [8] for the 22 63 approximation for the optimal test in Si and Liu (2013) [11], thus our approach is an 64 approximated optimal test. 65
Introduction 1
During the past decade, RNA sequencing (RNA-seq) technologies have revolutionized 2 transcriptomic studies. In a typical RNA-seq experiment, messenger RNA (mRNA) 3 molecules are extracted from samples, fragmented, and converted to a library of 4 complementary DNA (cDNA) fragments. The cDNA fragments are then amplified and 5 sequenced on a high-throughput platform, such as HiSeq by Illumina or SOLiD by 6 Applied Biosystems. Millions of DNA fragment sequences, called reads, are obtained for 7 each sample and mapped to a reference genome. The number of reads aligned to a given 8 gene measures the expression level for that gene. Thus, RNA-seq generates discrete 9 count data rather than continuous data serving as measurements of mRNA expression 10 levels. 11 In the statistical analysis of RNA-seq data, detecting differentially expressed (DE) 12 genes across treatments or conditions is one of the major steps and often the main goal. 13 A gene is considered to be DE if the expression levels change across treatment groups. detection of DE genes. 23 The comparison among all the popular methods for RNA-seq data analysis 24 mentioned above has been done through simulation studies [9, 10] . However, the 25 optimality of these existing testing procedures is inadequately studied. Si and Liu 26 (2013) [11] developed an optimal test for RNA-seq data anaysis while controlling FDR, 27 where optimal tests were defined as tests that achieve the maximum of the power 28 averaged across all genes for which null hypotheses are false. Furthermore, Si and Liu 29 (2013) [11] proposed an approximation to the optimal test, where hyper distributions 30 were estimated with mixture distributions, and such a test is called the approximated 31 most average powerful (AMAP) test. In the two-treatment comparison problem, Si and 32 Liu (2013) [11] modeled the gene-specific treatment means by the overall geometric 33 mean expression level across both treatments and the ratio of the two treatment means, 34 i.e., fold change ρ g . They used a K-component mixture Gamma-Normal (MGN) 35 distribution to model the joint distribution of the overall geometric mean expression 36 level and the logarithm of the fold change. However, there are several limitations of 37 using MGN distribution, such as difficulty in selecting an appropriate number of 38 components K, and challenges in modeling the empirical distribution of all genes by 39 parametric models. 40 Bayesian nonparametric modeling is a more flexible way for distribution estimation 41 and is often applied to avoid critical dependence on parametric assumptions. The most 42 popular Bayesian nonparametric methods adopt Dirichlet process (DP) mixture 43 modeling, and such modeling framework has been utilized for DE analyses. For 44 instance, [12] chose DP mixtures to model the population of genes under two different 45 conditions and applied to a microarray dataset. Liu et al. (2015) [13] used the DP prior 46 for modeling the distribution of fold changes between two treatments, with a mixture of 47 a point mass at one and a Gamma distribution as the base distribution in the DP prior. 48 In the method proposed by Liu et al. (2015) [13] , one treatment condition was set as 49 the reference condition (i.e., baseline) and they used DP as the prior for the distribution 50 of fold changes of the other condition versus the reference. When they changed the 51 reference treatment group, the declared differential expression status were not exactly 52 the same for all genes.
53
To address this issue that the model is not invariant to the choice of reference 54 condition, we propose a method using a mixture of three components as the base 55 distribution in the DP prior for the distribution of the fold changes between two 56 treatment conditions. The three components are a point mass at one, a Gamma, and an 57 inverse-Gamma distribution, so that the model becomes invariant no matter which 58 treatment group is set to be the reference. In addition, we model RNA-seq count data 59 via a Poisson-Gamma mixture model, which is equivalent to a NB model. Similar to Liu 60 et al. (2015) [13] , this paper shows how our mixture modeling procedure can be 61 accommodated to provide meaningful posterior probabilities of simple or composite null 62 hypothesis. Also, we show that the posterior inference can be viewed as an
Methods

73
In this section, we first describe the framework of our mixture modeling, and then 74 introduce the prior models employed in our method.
75
A Poisson-Gamma Mixture Model
76
Suppose that an RNA-seq experiment measures G genes. Let Y gij denote the number of reads mapped to gene g from biological replicate j of treatment i, where g = 1, . . . , G, i = 1, 2, j = 1, . . . , n i , and n i is the number of biological replicates in treatment i. As we mentioned in the introduction section, NB distribution has been popularly applied to such data. In the development of our modeling framework, we use a Poisson-Gamma mixture model parameterization instead of the NB model directly, where the RNA-seq read counts follow a Poisson distribution conditioning on the true expression mean, and the true gene abundances follow a Gamma distribution between replicate RNA samples. Then read count data Y gij can be modeled as below,
where S ij is a normalization factor that accounts for sequencing depth variation and 77 nuisance technical effects across the replicates, λ gij is the normalized expression mean 78 of jth replicate of ith treatment in gene g, α g is the shape parameter which stands for 79 the reciprocal of the dispersion parameter for gene g, β g is the rate parameter for the 80 first treatment, and the product of β g and ρ g is the rate parameter for the second 81 treatment. So the marginal expression mean for treatment 1 is α g /β g , while for 82 treatment 2 is α g /(β g ρ gi ). Therefore, the mean ratio of treatment 1 over treatment 2 is 83 ρ g , which refers to the fold change between treatment 1 versus treatment 2.
84
The goal of differential expression analysis is to test
for each gene g, where ∆ 0 represents the null set of values for ρ g , while ∆ 1 represents 85 the alternative set. ∆ 0 and ∆ 1 are assumed to be a partition of the positive real line R + 86
The null space ∆ 0 can be defined in different ways 87 depending on the biological problems of interest. For example, if we are interested in 88 identifying DE genes across the two treatments, we set ∆ 0 = {1}. If we are interested in 89 whether the mean expression level in the first treatment is greater than the second 90 treatment, we set ∆ 0 = (0, 1]. If we are interested in genes whose expression changes are 91 large enough, for instance, the fold changes are greater than 1.5 [14] , we set 92
93
Prior Specification
94
Since our main focus is to test the hypothesis about the fold change parameter ρ g in (2) 95 for each gene, specifying an appropriate prior distribution for ρ g is very crucial. The 96 empirical distribution of the fold change of all genes could be very irregular and differs 97 between various studies. To provide maximal flexibility, Bayesian nonparametric 98 modeling with DP is a common way for distribution estimation. DP is a stochastic 99 process whose realizations are probability distributions, i.e., each draw from a DP is 100 itself a distribution. The formal definition of DP is as follows. Given a measurable set 101 Ω, a base probability distribution F 0 and a positive real number M called the concentration parameter, a random probability distribution F is generated by a DP if 103 for any measurable partition A 1 , . . . , A k of Ω, the distribution of (F (A 1 ), . . . , F (A k )) is 104 Dirichlet D(M · F 0 (A 1 ), . . . , M · F 0 (A k )). We denote this by F ∼ DP (M, F 0 ). The and the DP will concentrate more of its mass around the mean.
110
Throughout our mixture modeling procedure, we use a DP to model the fold change 111 parameters (ρ 1 , . . . , ρ G ). Different from Liu et al. (2015) [13] , we use a mixture of a 112 point mass at one, a Gamma and an inverse-Gamma distribution as the base 113 distribution in the DP prior for the distribution of the fold change parameters, so that 114 our modeling is invariant to the specification of the reference condition, and we call it 115 iSBA (where SBA stands for semiparametric Bayesian approach). Details of the proof of 116 reference level invariance are provided in S1 Appendix.
117
Therefore, the DP prior for gene g, g = 1, . . . , G, can be expressed as
where p 0 is the proportion of EE genes, and δ {x} denotes a point mass at x. In this 118 paper, we set p 0 = 0.5 to give no prior preference to either DE or EE. The 119 concentration parameter M in the DP priors is fixed as M = 1, which is a common 120 choice used in application [12, 15, 16] . Throughout our paper, the simple null hypothesis 121 of our great interest is H g 0 : ρ g = 1.
122 Following Liu et al. (2015) [13] , we use a Gamma distribution as the prior distribution for β g due to its conjugacy, and an exponential distribution as the prior for α g in order to reduce the computational complexity of the posterior distribution,
where r, a 0 , b 0 , in addition to α 0 and β 0 in (3), are hyperparameters. We set r = 0.01, 123 a 0 = 0.1, b 0 = 0.1, α 0 = 0.1, β 0 = 0.1 so that the priors are non-informative and the 124 inference for α g and β g mainly relies on the observed data. For computational 125 simplicity, we set the priors for α g 's, β g 's, and ρ g 's to be independent. algorithm [18] .
136
The Metropolis-Hastings algorithm simulates samples from a target distribution π(x) using a proposal distribution g(x * |x), and updates the state x as follows. Generate a candidate state x * from the distribution g(x * |x), then compute the acceptance probability
Set the new state x to x * with probability a(x * |x). Otherwise, reject the candidate x * 137 and let x be the same as x.
138
To simplify the use of DP prior, when F is integrated over its prior distribution (3), the sequence of ρ g 's follows a Polya urn scheme [19, 20] , that is,
where ρ −g is the vector of (ρ 1 , . . . , ρ G ) after deleting ρ g .
139
Then the most direct approach to sample for our model is to perform Metropolis-Hastings update for each of the ρ g . However, this algorithm may not be very efficient since it cannot change the ρ g for more than one gene simultaneously. A change to the ρ g values occurs only when they are reallocated to new components. Thus it may take long time to converge to the posterior distribution [21] . In order to improve the efficiency of the MCMC algorithm, a modified Metropolis-Hastings updates and partial Gibbs sampling method has been proposed by Neal (2000) [21] (Algorithm 7). Suppose K is the number of distinct values in the vector (ρ 1 , . . . , ρ G ) and the distinct values are denoted as ρ * 1 , . . . , ρ * K , respectively. Let ξ = (ξ 1 , . . . , ξ G ) be the configuration indicators defined by ξ g = k if and only if ρ g = ρ * k = ρ * ξg . Therefore, we reparameterize the prior model for ρ g 's with ρ * k 's and ξ g 's as follows,
where the prior models for ρ * k 's and ξ g 's are independent and CRP stands for Chinese Restaurant Process. CRP is a random distribution and the full conditional distribution for ξ g 's can be written as
where K (−g) denotes the number of distinct values in the vector (ρ 1 , . . . , ρ G ) after 140 deleting ρ g , and n (−g) k denotes the number of (ρ 1 , . . . , ρ G ) who equal ρ * k after deleting 141 ρ g .
142
The MCMC sampling scheme uses the modified Metropolis-Hastings updates and 143 partial Gibbs sampling method to repeatedly sample the following parameters step by 144 step. The procedure for generating the full conditionals of all parameters and how we 145 apply Metropolis-Hastings algorithm are shown in S2 Appendix.
146
(1) Draw samples of λ gij 's from their full condition distributions,
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(2) Draw samples of β g 's from their full conditional distributions,
(3) There is no closed-form full conditional distribution for α g 's. Since the conditional 147 posterior distribution for each gene g is a log-concave function with respect to α g , 148 we could draw posterior samples based on adaptive rejection sampling method [22] . 149
(4) Obtain posterior samples for ρ g 's by getting the Markov chain for (ξ 1 , . . . , ξ G ) and 150 (ρ * 1 , . . . , ρ * K ) as follows:
151
(i) Update the configuration vector (ξ 1 , . . . , ξ G ).
152
• For g = 1, . . . , G, repeat the following: If ξ g = ξ l for some l = g, let ξ * g be a newly created component, with ρ * ξ * g drawn from F 0 . Set ξ g to ξ * g with probability
.
• For g = 1, . . . , G, if ξ g = ξ l for all l = g, do nothing. Otherwise, choose a new value for ξ g from {ξ 1 , . . . , ξ G } with probabilities
where b is the appropriate normalizing constant.
153
(ii) Update (ρ * 1 , . . . , ρ * K ). For k = 1, . . . , K, repeat the following: Draw ρ * * k from F 0 . Set the new value of ρ * k to ρ * * k with the probability a(ρ * * k , ρ * k ) = min 1, e {g:ξg =k}
Otherwise, let the new ρ * k be the same as the old value. If we have 154 duplicated ρ * k , delete it and combine ξ g .
155
Bayesian FDR Control
156
In genomic studies, tens of thousands of hypotheses are simultaneously tested, each
For each gene g, g = 1, . . . , G, the posterior probability that gth null hypothesis is true is denoted by P (ρ g ∈ ∆ 0 |Y g ). If we are interested in detecting DE genes, with ∆ 0 = {1}, P (ρ g ∈ ∆ 0 |Y g ) is the posterior probability that gene g is EE. P (ρ g ∈ ∆ 0 |Y g ) can be estimated by the proportion of the posterior samples obtained from MCMC for gene g that fall into the null set ∆ 0 , i.e.,
where N is the number of posterior samples. We reject H g 0 if the estimated posterior probabilityv g is smaller than a critical value c * . The critical value c * is chosen based on controlling the FDR at a target level γ, for example, 0.05, i.e.,
So the Bayesian FDR controlled at level γ can be calculated by
Results
164
In this section, we adopt the simulation settings in Liu et al. (2015) [13] to assess the 165 performance of our proposed method (iSBA), and compare to their semi-parametric 166 Bayesian (SBA) method along with other popular methods for differential expression 167 analysis of RNA-seq data, such as edgeR [3] , voom and limma pipeline [7] , and 168 DESeq [5] . To mimic the distributions of real RNA-seq count data, we sampled 169 gene-specific mean and dispersion parameters from the estimated values based on a 170 maize study [26] that compared gene expression between bundle sheath and mesophyll 171 cells of corn plants. Following Liu et al. (2015) [13] , we conducted the same two sets of 172 simulation studies (A and B). For each simulation study, 32 independent RNA-seq 173 datasets were simulated from NB distributions with given mean and dispersion 174 parameters, each dataset contains 10,000 genes, 2 treatment groups, and n replicates 175 per treatment group, where n = 3 or 6. For our proposed method, we generated 5000 176 posterior samples after 3000 iterations burn-in, to calculate the estimated posterior 177 probabilities. Convergence was checked via Gelman-Rubin criteria [27] . The test 178 performances of different methods are evaluated by averaging the 32 datasets. the control group (µ g ) and the true dispersion parameter (φ g ) for gene g = 1, . . . , 10000. 185 Given the number of replicates per treatment group, n = 3 or 6, the RNA-seq read 186 count data for the control group were generated from N B(µ g , φ g ) for gene g. Then we 187 October 2, 2018 7/13 randomly selected 5000 out of the 10,000 genes to be EE, whose count data for the 188 treatment group were also drawn from N B(µ g , φ g ). The remaining 5000 genes were 189 simulated to be DE genes, with fold change (ρ g ) set to be 4, 8, 0.25 and 0.125. Thus we 190 had 1250 genes for each ρ g value, whose count data for the treatment group were drawn 191 from N B(µ g ρ g , φ g ).
192
Simulation B
193
Similar to Simulation A, we generated 10,000 genes from N B(µ g , φ g ), with fold change ρ g for 5000 DE genes. Instead of setting ρ g to be 4, 8, 0.25 or 0.125, we simulated ρ g from a two-component mixture of lognormal distributions, log(ρ g ) ∼ 0.5Normal(log(4), 1) + 0.5Normal(−log(4), 1). For each level of FPR, the TPRs were averaged over the 32 simulated datasets. The percentage reported in the legend is the average AUC for each method, representing the percentage of 0.1, which is the total area in the range of FPR < 0.1, and the percentage in each set of parentheses is the standard deviation of the estimated AUC.
Simulation Results for Testing DE Genes
We also checked the false discovery (FD) plot as in Liu et al. (2015) [13] , which is 212 the plot of the number of false positives versus the number of top ranked genes selected 213 as DE. Genes were ranked based on either posterior probabilities or p−values for each 214 method. A better performing method would have a lower FD curve. The FD plots for 215 Simulations A and B with n = 3 or 6 are shown in Fig 2. The number of false positives 216 decreased when sample size increased from 3 to 6 for all methods, as expected. Our 217 iSBA method and the SBA method provided the lowest FD curves under all simulation 218 settings, indicating that our iSBA method and the SBA method produced less false 219 positives than others, when we declared the same number of DE genes for all methods.
220
In addition, we evaluated the estimation of FDR based on subsection "Bayesian are presented in Fig 3. Our iSBA method controlled FDR well, the SBA method 225 performed the second, while other methods provide more conservative results. 
232
Simulation Results for Testing: |logF C| ≤ log1.5
233
In addition to the simple hypothesis testing problem introduced in the last subsection, 234 we could also apply our method to do other types of hypothesis testing, for example, 235 testing whether the fold change falls into a certain interval or not. In practice, biologists 236 often want to detect genes whose fold-changes are big enough and biologically 237 meaningful. This subsection shows the results for testing: |logF C| ≤ log1.5 for 238 Simulation B.
239
We applied our iSBA method and the SBA method directly to do this hypothesis 240 testing problem. For other methods including edgeR, voom and limma pipeline, and 241 DESeq, we adopted the two-step procedure described in [11] . More specifically, in the 242 first step, ρ g = 1 was tested for each gene, and a list of DE genes was identified while 243 controlling FDR at a given level. In the second step, among those DE genes declared in 244 the first step, genes with large enough fold changes (|logF C| > log1.5) were selected. As we discussed in the Introduction Section, the semi-parametric Bayesian (SBA) 251 method [13] set one treatment group as reference condition. If the choice of a reference 252 condition is not obvious based on the experimental design, the declared differential expression status may vary depending on which group is set to be baseline. However, 254 the model we proposed is invariant no matter which group is set to be the reference 255 condition. The proportion of genes remaining the same declared differential expression 256 status between two analyses that swapped the treatment and control groups were 257 calculated when controlling FDR at 0.05, with average values and standard deviation of 258 the percentage across the 32 simulated datasets reported in Table 1 . It turned out that 259 our iSBA method had higher overlap and more consistency in declared differential 260 expression status than SBA method when swapping the treatment and control groups, 261 for all simulation settings.
262 Table 1 . Proportion of genes remaining the same declared differential expression status between two analyses that swapped the treatment and control groups for Simulations A and B, when controlling FDR at 0.05. The proportions were averaged across the 32 simulated datasets, and the percentage in each set of parentheses is the standard deviation of the estimated proportion. In this subsection, we analyze a real RNA-seq dataset published by Li et al. (2010) .
264
The dataset measures the transcript abundance of two cell types, bundle sheath and 265 mesophyll, for different leaf sections. Each cell type has two biological replicates. The 266 objective of the analysis is to detect genes that are DE between cell types or between 267 different leaf sections. We analyzed leaf section 4 to detect DE genes between the two 268 cell types in this section. 269 After deleting genes that have zero counts for both replicates in either cell type, 270 28,407 out of 33,743 genes were retained for analysis. We assumed NB models for the 271 count data observed for each gene, and performed our proposed iSBA method, together 272 with SBA method and edgeR. We also controlled FDR as described in subsection 273 "Bayesian FDR Control" for SBA and iSBA, and applied the Benjamini and 274 Hochberg [23] procedure for edgeR.
275
The numbers of DE genes detected by different methods while controlling FDR at 276 different levels are shown in Fig 5. For example, when we controlled FDR at 0.05, 6040 277 genes were detected by all three methods. The majority of genes identified by our iSBA 278 method were overlapped with SBA. 2703 genes were detected by both iSBA and SBA, 279 but not by edgeR, which may due to the conservative control of FDR based on our 280 simulation studies. The Venn diagram on the left shows the number of overlapping identified DE genes from our iSBA method, SBA method, and edgeR while controlling FDR at 1%; the Venn diagram on the right shows the corresponding results while controlling FDR at 5%.
The proportions of genes remaining the same declared differential expression status 282 between two analyses that swapped the two treatment groups when controlling FDR at 283 0.05 for our iSBA method is 93.47%, while the SBA method is 89.28%.
Discussion
285
In this paper, we proposed a Bayesian mixture modeling procedure for DE analysis of 286 RNA-seq count data, and employed the MCMC sampling scheme to generate posterior 287 samples for further inference. Simulation results demonstrate that our method 288 outperformed other commonly used methods, such as edgeR, voom and limma pipeline, 289 and DESeq, in terms of both ranking DE genes and FDR control.
290
A common choice of the concentration parameter M in the DP priors that are 291 widely used in application is M = 1 [12] . We check the simulation results with different 292 M values (M being 0.2, 0.5, 2, 5, 10 or 20), and the results remain almost the same for 293 various values of M .
294
In our proposed method, the DP prior we choose guarantees that our modeling is 295 invariant regardless of which treatment group is set to be the reference condition.
296
According to the simulation results on two analyses that swapped the treatment and 297 control groups, it is worth noticing that even for our iSBA method, the declared 298 differential expression status are still not 100% the same. Part of the reason is due to 299 the randomness of MCMC, if we run another MCMC using different seed, the overlap 300 between the two MCMCs is about 97%. Since we generated 5000 posterior samples to 301 calculate the estimated posterior probabilities after 3000 iterations burn-in, whether the 302 Markov chains are long enough to get accurate results is also a potential problem. We 303 checked the effective sample size for each gene, genes that had the same declared DE 304 status after swapping treatments had effective sample sizes about 500 or larger, but 305 genes that had different declared DE status overlapped had effective sample sizes 306 around only 100. Effective sample size around 400 can be regarded as large enough, so 307 for those genes with low effective sample size, we may need to run longer MCMC. Based 308 on simulation checking, running the Markov chains longer do increase the percentage of 309 overlapping genes, as expected. For example, for simulation A with n = 6, if we doubled 310 the length of chain, the overlap for iSBA increased to 95.28%. However, running longer 311 chains is more time consuming, and it only benefits a small proportion of genes while 312 results for most genes would not change. Therefore, it is a tradeoff between efficiency 313 and accuracy, and we will let the users decide which one is more important for a 314 practical application.
315
As indicated in subsection "Bayesian FDR Control", the estimated posterior 316 probabilityv g is used as a test statistic and a decision D g is based on whetherv g is 317 small enough. And the AMAP test by Si and Liu (2013) [11] is based on a similar test 318 statistic except that the prior models are different. In fact, the MAP test statistic 319 derived in Si and Liu (2013) [11] can be viewed as the posterior probability of being null 320 given the distribution of gene-specific parameters under the null hypothesis and the 321 distribution of these parameters under the alternative hypothesis. Assuming the 322 distributions of the gene-specific parameters (fold changes and other parameters) follow 323 approximately the prior distribution we use, our estimated posterior probability using 324 MCMC is an AMAP test statistic. 
